Improving T-Cell Therapy for Epstein-Barr Virus Lymphoproliferative Disorders
Menée sur 10 patients atteints d'un syndrome lymphoprolifératif lié au virus d'Epstein-Barr après une greffe allogénique de cellules souches, cette étude évalue la faisabilité d'un transfert adoptif de lymphocytes T spécifiques de l'antigène EBNA-1
More than 90% of the population is infected with Epstein-Barr virus (EBV), which is an enveloped herpesvirus. EBV infection in immunocompetent individuals causes a mild self-limiting illness, but the virus persists lifelong as a latent infection in B cells and spreads in the community by productive replication in B cells and oral epithelial cells. EBV latency varies in the number and type of EBV proteins expressed by B cells. In type 3 latency, all nine latency-associated EBV proteins are expressed. SuchBcells express cell adhesion and costimulator molecules rendering them immunogenic and susceptible to immune-mediated killing by EBV-specific cytotoxic T lymphocytes (CTLs). After hematopoietic stem-cell transplantation (HSCT) without functional CTLs, type 3 latency EBV- infected B cells proliferate unchecked. EBV-infected B cells cause a lymphoproliferative disorder that can progress to lymphoma with increased levels of EBV DNA detected by polymerase chain reaction (PCR)...
Journal of Clinical Oncology , éditorial en libre accès, 2012